178 related articles for article (PubMed ID: 36461172)
1. Risk of recurrent thromboembolic events according to treatment duration in patients with superficial vein thrombosis treated with intermediate dose of tinzaparin.
Karathanos C; Kakkos SK; Georgiadis G; Ioannou C; Vasdekis S; Chatzis D; Latzios P; Giannoukas AD;
Phlebology; 2023 Apr; 38(3):141-149. PubMed ID: 36461172
[TBL] [Abstract][Full Text] [Related]
2. Treatment of superficial vein thrombosis with intermediate dose of tinzaparin: A real word cohort study - The SeVEN EXTension study.
Karathanos C; Chatzis D; Latzios P; Papakostas I; Goumas K; Giannoukas AD;
Phlebology; 2021 Jul; 36(6):423-431. PubMed ID: 33407054
[TBL] [Abstract][Full Text] [Related]
3. Tinzaparin in intermediate dose for the treatment of superficial vein thrombosis: Results from an observational multicenter study-SeVEN study.
Giannoukas A; Karathanos C; Nikolakopoulos K; Georgiadis GS; Maltezos C; Ioannou C; Vasdekis S; Trelopoulos G;
Phlebology; 2018 Oct; 33(9):636-645. PubMed ID: 29277133
[TBL] [Abstract][Full Text] [Related]
4. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
[TBL] [Abstract][Full Text] [Related]
5. Determinants of Late Venous Thromboembolic Events After Acute Isolated Superficial Vein Thrombosis in Daily Practice: 12 Month Results of the INSIGHTS-SVT Study.
Rabe E; Hoffmann U; Schimke A; Heinken A; Langer F; Noppeney T; Pittrow D; Klotsche J; Gerlach HE; Bauersachs R;
Eur J Vasc Endovasc Surg; 2023 Nov; 66(5):697-704. PubMed ID: 37573936
[TBL] [Abstract][Full Text] [Related]
6. Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin.
Hyers TM; Spyropoulos AC;
J Thromb Thrombolysis; 2007 Dec; 24(3):225-32. PubMed ID: 17334932
[TBL] [Abstract][Full Text] [Related]
7. Long-term risk of venous thromboembolism recurrence after isolated superficial vein thrombosis.
Galanaud JP; Sevestre MA; Pernod G; Kahn SR; Genty C; Terrisse H; Brisot D; Gillet JL; Quéré I; Bosson JL
J Thromb Haemost; 2017 Jun; 15(6):1123-1131. PubMed ID: 28317330
[TBL] [Abstract][Full Text] [Related]
8. Superficial vein thrombosis and recurrent venous thromboembolism: a pooled analysis of two observational studies.
Galanaud JP; Bosson JL; Genty C; Presles E; Cucherat M; Sevestre MA; Quere I; Decousus H; Leizorovicz A
J Thromb Haemost; 2012 Jun; 10(6):1004-11. PubMed ID: 22429908
[TBL] [Abstract][Full Text] [Related]
9. Management and Outcomes of Patients with Isolated Superficial Vein Thrombosis under Real Life Conditions (INSIGHTS-SVT).
Bauersachs R; Gerlach HE; Heinken A; Hoffmann U; Langer F; Noppeney T; Pittrow D; Klotsche J; Rabe E
Eur J Vasc Endovasc Surg; 2021 Aug; 62(2):241-249. PubMed ID: 34210599
[TBL] [Abstract][Full Text] [Related]
10. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients.
Lee AY; Bauersachs R; Janas MS; Jarner MF; Kamphuisen PW; Meyer G; Khorana AA;
BMC Cancer; 2013 Jun; 13():284. PubMed ID: 23764005
[TBL] [Abstract][Full Text] [Related]
11. Thromboembolic complications following a first isolated episode of superficial vein thrombosis: a cross-sectional retrospective study.
Bell LN; Berg RL; Schmelzer JR; Liang H; Mazza JJ; Kanth R; Bray CL; Zaldivar CB; Yale SH
J Thromb Thrombolysis; 2017 Jan; 43(1):31-37. PubMed ID: 27565478
[TBL] [Abstract][Full Text] [Related]
12. A systematic review and meta-analysis for the association between duration of anticoagulation therapy and the risk of venous thromboembolism in patients with lower limb superficial venous thrombosis.
Lobastov K; Dubar E; Schastlivtsev I; Bargandzhiya A
J Vasc Surg Venous Lymphat Disord; 2024 Mar; 12(2):101726. PubMed ID: 38008180
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of deep vein thrombosis and pulmonary embolism in patients with superficial vein thrombosis: a systematic review and meta-analysis.
Di Minno MN; Ambrosino P; Ambrosini F; Tremoli E; Di Minno G; Dentali F
J Thromb Haemost; 2016 May; 14(5):964-72. PubMed ID: 26845754
[TBL] [Abstract][Full Text] [Related]
14. Medical management of acute superficial vein thrombosis of the saphenous vein.
Scovell SD; Ergul EA; Conrad MF
J Vasc Surg Venous Lymphat Disord; 2018 Jan; 6(1):109-117. PubMed ID: 29097174
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum).
Cosmi B; Filippini M; Campana F; Avruscio G; Ghirarduzzi A; Bucherini E; Camporese G; Imberti D; Legnani C; Palareti G;
Thromb Res; 2014 Feb; 133(2):196-202. PubMed ID: 24365043
[TBL] [Abstract][Full Text] [Related]
16. Extended-Duration Treatment of Superficial Vein Thrombosis of the Lower Limbs with Tinzaparin.
Nikolakopoulos KM; Kakkos SK; Papageorgopoulou CP; Tsolakis IA
Vasc Specialist Int; 2018 Mar; 34(1):1-9. PubMed ID: 29629359
[TBL] [Abstract][Full Text] [Related]
17. Tinzaparin in outpatients with pulmonary embolism or deep vein thrombosis.
Dager WE; King JH; Branch JM; Chow SL; Ferrer RE; Pak S; Togioka PY; White RH
Ann Pharmacother; 2005; 39(7-8):1182-7. PubMed ID: 15956232
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
[TBL] [Abstract][Full Text] [Related]
19. Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study.
Decousus H; Quéré I; Presles E; Becker F; Barrellier MT; Chanut M; Gillet JL; Guenneguez H; Leandri C; Mismetti P; Pichot O; Leizorovicz A;
Ann Intern Med; 2010 Feb; 152(4):218-24. PubMed ID: 20157136
[TBL] [Abstract][Full Text] [Related]
20. OC-14 - Baseline D-dimer levels are predictive of recurrent venous thromboembolism (VTE) at 6 months in cancer patients with VTE treated with tinzaparin.
Piatek CI; Tagawa ST; Wei-Tsai D; Hanna D; Weitz IC; O'Connell C; Rochanda L; Groshen S; Liebman HA
Thromb Res; 2016 Apr; 140 Suppl 1():S174. PubMed ID: 27161687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
